



## Digenic Alport Syndrome

This is the peer reviewed version of the following article:

*Original:*

Savige, J., Renieri, A., Ars, E., Daga, S., Pinto, A.M., Rothe, H., et al. (2022). Digenic Alport Syndrome. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 17(11), 1697-1706 [10.2215/CJN.03120322].

*Availability:*

This version is available <http://hdl.handle.net/11365/1223539> since 2023-01-11T15:44:19Z

*Published:*

DOI:10.2215/CJN.03120322

*Terms of use:*

Open Access

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. Works made available under a Creative Commons license can be used according to the terms and conditions of said license.

For all terms of use and more information see the publisher's website.

(Article begins on next page)

## Digenic Alport syndrome

<sup>1</sup>Judy Savige, <sup>2,3,4</sup>Alessandra Renieri, <sup>5</sup>Elisabet Ars, <sup>2,3</sup>Sergio Daga, <sup>4</sup>Anna Maria Pinto, <sup>6</sup>Hansjorg Rothe, <sup>7</sup>Daniel P Gale, <sup>8</sup>Marina Aksenova, <sup>9</sup>Agne Cerkauskaite, <sup>10</sup>Olga Bielska, <sup>10</sup>Beata Lipska-Zietkiewicz and <sup>1</sup>Joel T Gibson

<sup>1</sup>The University of Melbourne Department of Medicine (Melbourne Health and Northern Health); <sup>2</sup>Medical Genetics, University of Siena, Siena, ITALY; <sup>3</sup>Med Biotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Siena, Italy; <sup>4</sup>Genetics Medica, Azienda Ospedaliero-Universitaria Senese, Siena, Italy; <sup>5</sup>Molecular Biology Laboratory, Fundacio Puigvert, Instituto de Investigaciones Biomédicas Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona, Barcelona, SPAIN; <sup>6</sup>Centre for Nephrology and Metabolic Disorders, D-02943 Weisswasser, GERMANY; <sup>7</sup>Department of Renal Medicine, University College London, London, UNITED KINGDOM; <sup>8</sup>Veltischev Research and Clinical Institute for Pediatrics of the Pirogov Russian National Research Medical University, Moscow, RUSSIA; <sup>9</sup>Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University Vilnius, LITHUANIA; and <sup>10</sup>Centre for Rare Diseases, and Clinical Genetics Unit, Medical University of Gdansk, POLAND.

Address for Correspondence:

Prof Judy Savige

The University of Melbourne

Department of medicine (Melbourne Health and Northern Health)

Royal Melbourne Hospital

Parkville VIC 3050

AUSTRALIA

## **Abstract**

Digenic Alport syndrome refers to the inheritance of pathogenic variants in *COL4A5* plus *COL4A3* or *COL4A4*; or in *COL4A3* plus *COL4A4*.

Where digenic Alport syndrome includes a pathogenic *COL4A5* variant, the consequences depend on the sex of the affected individual, *COL4A5* variant 'severity', and the nature of the *COL4A3* or *COL4A4* change. A male with a pathogenic *COL4A5* variant has all his collagen IV  $\alpha3\alpha4\alpha5$  heterotrimers affected, and an additional *COL4A3* or *COL4A4* variant may not worsen disease. A female with a pathogenic *COL4A5* variant has on average 50% of her heterotrimers affected which is increased to 75% with a further *COL4A3* or *COL4A4* variant, and associated with an increased risk of proteinuria.

In digenic Alport syndrome with pathogenic *COL4A3* and *COL4A4* variants, 75% of the heterotrimers are affected. The *COL4A3* and *COL4A4* genes occur head-to-head on chromosome 2, and inheritance is autosomal dominant when both variants affect the same chromosome (in cis) or recessive when they affect different chromosomes (in trans). This form of digenic disease results in increased proteinuria, and a median age of kidney failure intermediate between AD and AR Alport syndrome.

Previous guidelines have suggested that all Pathogenic or Likely Pathogenic digenic variants should be identified and reported. Affected family members should be identified, treated and discouraged from kidney donation. Inheritance within a family is easier to predict if the two variants are considered independently and if *COL4A3* and *COL4A4* variants are known to be inherited on the same or different chromosomes.

## Text

Alport syndrome (OMIM#301050) is the second commonest cause of genetic kidney failure after polycystic kidney disease<sup>1,2</sup>. Inheritance is X-linked where there is a single pathogenic variant in the *COL4A5* gene, and autosomal recessive where there are pathogenic variants in both copies of the *COL4A3* or *COL4A4* genes. Autosomal dominant Alport syndrome is sometimes used where there is a heterozygous pathogenic *COL4A3* or *COL4A4* variant, but the term is incorrect since extrarenal or syndromic features are lacking. This condition is also known as Thin basement membrane nephropathy<sup>3</sup>. The three *COL4A3* – *COL4A5* genes code for the collagen IV  $\alpha 3$  –  $\alpha 5$  chains which form the collagen IV  $\alpha 3\alpha 4\alpha 5$  heterotrimer<sup>4</sup>. A network of these trimers forms the backbone of the basement membranes in the kidney, ear and eye<sup>4</sup>.

The distinguishing features of all forms of Alport syndrome are persistent haematuria and a family history of haematuria and sometimes kidney failure together with basement membrane thinning or lamellation<sup>5</sup>. Proteinuria and focal and segmental glomerulosclerosis are recognised increasingly<sup>6</sup>. Hearing loss, lenticonus and fleck retinopathy are also common but the hearing loss may be coincidental and the ocular abnormalities may not be recognised.

Males with X-linked Alport syndrome and males and females with autosomal recessive disease have a similar phenotype with kidney failure, hearing loss, lenticonus and a fleck retinopathy. Ninety % of males with X-linked disease have kidney failure by the age of 40 years<sup>7</sup>. Fifteen – 30% of females with X-linked disease have kidney failure by the age of 60, and hearing loss and fleck retinopathy are common but lenticonus does not occur<sup>8</sup>. Most individuals with AD Alport syndrome have haematuria only, and while a few develop proteinuria and kidney failure, hearing loss and ocular abnormalities are very rare.<sup>9, 10</sup>

Two further forms of inheritance are now recognised, and definitions differ, but the following interpretations have been adopted for Alport syndrome<sup>3</sup>. ‘Digenic’ disease refers to two pathogenic variants in different *COL4A3* – *COL4A5* genes<sup>11</sup>. This differs from ‘modifying’ variants where a heterozygous pathogenic *COL4A3*- *COL4A5* variant occurs together with a pathogenic change in a gene encoding another podocyte or glomerular filtration barrier protein<sup>12, 13</sup>.

Some geneticists prefer to use ‘double heterozygotes’ rather than digenic variants where the pathogenic changes affect genes that on their own cause disease. However digenic disease is used here to be consistent with the recent classification of Alport syndrome and previous reports<sup>3, 11, 14-16</sup>. Digenic inheritance refers to variants at two loci that explain the phenotype of some affected individuals better than a variant at one locus alone<sup>17</sup>. Both loci may be equally important, but one may also increase the disease risk or severity<sup>17, 18</sup>. The outcome depends on whether the affected individual is a male with a *COL4A5* change in which case all heterotrimers are already affected. The second variant may also determine who develops clinical features, or has disease at a younger age. This is because the second variant usually increases the proportion of heterotrimers that are defective. While digenic disease contributes to the variability of clinical features in some families, this is not a common finding.

### **Types of digenic inheritance**

Digenic Alport syndrome is due to a pathogenic variant in *COL4A5* plus one in *COL4A3* or *COL4A4* or due to a pathogenic variant in *COL4A3* plus one in *COL4A4*. These will be considered separately because their population frequencies, mode of inheritance, and molecular and clinical consequences are different. For digenic variants affecting *COL4A5* plus *COL4A3* or *COL4A4*, many of these features depend on whether the *COL4A5* variant affects a male or female, and in all cases, variant 'severity' also contributes to the phenotype<sup>19</sup>

### **Pathogenic variants in *COL4A5* plus *COL4A3* or *COL4A4* in males or females**

The number of published reports of digenic Alport syndrome has increased with the widespread adoption of Massively Parallel Sequencing for routine genetic testing. Massively Parallel Sequencing has dramatically increased the ability to detect multiple variants in different genes contemporaneously in a single individual. Previous practice was to sequence the *COL4A3* – *COL4A5* genes where there were the characteristic features of X-linked or autosomal recessive Alport syndrome, that is, kidney failure, hearing loss, and ocular abnormalities. Once a pathogenic variant was found the laboratory ceased to look for a further change. This meant that few digenic variants were identified, most included a pathogenic *COL4A5* change, and only some of the digenic variants identified as such in a publication.

Here we have reviewed all the published digenic variants found in a literature search and after requests to testing laboratories attending the 2021 International Workshop on Alport syndrome<sup>20</sup>, and where at least some clinical data (age, sex, proteinuria, age at kidney failure) were also available. This strategy identified 43 *COL4A5* plus *COL4A3*/*COL4A4* variants and 32 *COL4A3* plus *COL4A4* variants.

It is however possible to deduce the relative population frequencies of digenic variants more accurately from recently published data for pathogenic variants in *COL4A5* of about one in 2,000, and for *COL4A3* or *COL4A4* of about one in 100<sup>1</sup>. Thus, digenic inheritance of a *COL4A5* variant plus a *COL4A3* or *COL4A4* variant occurs in about  $1/2000 \times 1/100 = 1/200,000$ , if both occur independently, and in about one % of all individuals with X-linked Alport syndrome. This was confirmed in a study of 417 mainly children with suspected Alport syndrome where 6 had pathogenic variants in both *COL4A5* and *COL4A3* or *COL4A4*<sup>21</sup>.

**Inheritance.** With *COL4A5* plus *COL4A3*/*COL4A4* variants, the variants are inherited independently from one parent or from both. In these cases, inheritance of the individual *COL4A5* plus *COL4A3*/*COL4A4* variants each resemble the inheritance pattern of the underlying variant, namely X-linked or autosomal dominant. Inheritance in an individual family is easier to understand if the inheritance of each variant is considered separately.

Thus, for a male with a pathogenic *COL4A5* variant none of his sons will inherit the *COL4A5* variant, but all of his daughters will, and half his sons and half his daughters will inherit the *COL4A3* or *COL4A4* variant. Thus none of his sons have digenic disease but half his daughters will.

For a female with a pathogenic *COL4A5* variant as well as a pathogenic *COL4A3* or *COL4A4* variant, half her sons and half her daughters will inherit the pathogenic *COL4A5* variant, and, as an independent event, half her sons and half her daughters will inherit the pathogenic *COL4A3* or *COL4A4* variant. Thus, if she had four children, on average, one has a *COL4A5* variant plus a *COL4A3* or *COL4A4* variant (and digenic disease), one has a *COL4A5* variant only, one a *COL4A3* or *COL4A4* variant only, and one has none.

The clinical consequences also depend on the effect of the variants on the collagen IV  $\alpha$  chains and whether they affect the interaction of the impaired chains.

**Disease pathogenesis.** In order to understand the effects of an additional pathogenic variant it is important to understand why some pathogenic *COL4A5* variants result in more severe disease and more pronounced proteinuria or earlier onset kidney failure.

Pathogenic *COL4A5* variants that result in severe disease include truncating variants, major rearrangements, large deletions, and splicing variants that induce exon skipping or intronic retention<sup>7, 19</sup>. Premature stop codons typically result in nonsense mediated decay of the mRNA transcript and absence of the collagen IV  $\alpha3\alpha4\alpha5$  heterotrimer from affected membranes<sup>22</sup>. 'Severe' *COL4A5* variants result in severe disease with early onset kidney failure, hearing loss, and often lenticonus and central fleck retinopathy. In contrast, missense variants typically produce less disruption of the collagen IV  $\alpha$  chains which may be partly retained within the endoplasmic reticulum resulting in increased associated stress. However the collagen IV  $\alpha$  chains also persist in smaller amounts within the affected membranes<sup>23, 24</sup>. These variants are associated with milder disease with later onset kidney failure, hearing loss, and less often with lenticonus. Hypomorphic variants also result in mild disease with late onset proteinuria, and kidney failure in the sixth or seventh decade often without hearing loss, lenticonus or the central fleck retinopathy<sup>25, 26</sup>. These variants include Gly substitutions that are adjacent to a non-collagenous sequence or a non-Gly substitution. The p.Gly624Asp substitution is a common hypomorphic *COL4A5* variant in people of European ancestry<sup>26</sup>.

On their own, heterozygous pathogenic *COL4A3* and *COL4A4* variants typically have a less severe effect than pathogenic heterozygous *COL4A5* variants. They usually result in haematuria, and sometimes proteinuria, but kidney failure is less likely, and hearing loss, lenticonus and fleck retinopathy are very rare if they occur at all<sup>9, 10</sup>. Sometimes there is no haematuria or proteinuria.

**Pathogenic variants in *COL4A5* plus *COL4A3* or *COL4A4* in males.** The major consequences of digenic variants where one affects *COL4A5* depends on the sex of the individual and the variant severity. In males, a *COL4A5* variant affects all the collagen IV  $\alpha3\alpha4\alpha5$  heterotrimers (**Figure 1a**). If the *COL4A5* variant is already 'severe' (a large rearrangement, truncating or splice variant) the heterotrimers are often absent and kidney failure is likely before the age of 30<sup>7</sup>. Even the addition of even a severe *COL4A3* or *COL4A4* variant may have no consequences since the collagen IV  $\alpha3$  and  $\alpha4$  chains are destroyed rather than being expressed in basement membranes. However, if the *COL4A5* variant is a missense variant resulting in milder or hypomorphic disease then the collagen IV  $\alpha3\alpha4\alpha5$  heterotrimer is

abnormal and the additional *COL4A3* or *COL4A4* variant may further disrupt half of the already abnormal heterotrimers (**Figure 1a**).

While these effects are likely, it is still difficult to confirm that the combination of a *COL4A5* and *COL4A3* or *COL4A4* variant results in worse disease because so few individuals with digenic disease have been described, many affected children are too young to have kidney failure, and GBM lamellation, hearing and ocular defects may not be known. Common clinical data is often sparse, and rarely includes the age at which proteinuria was first detected, which is often more relevant than age at kidney failure.

In addition, some individuals reported with a *COL4A5* variant may have an undetected pathogenic variant in *COL4A3* or *COL4A4*. In addition, other extra-renal factors are also important in the risk of kidney failure such as hypertension control, and avoiding diabetes and becoming overweight<sup>27, 28</sup>. Furthermore, the age at kidney failure has been further delayed with the widespread use of ACE inhibitor treatment<sup>29</sup>.

A review of all reported digenic *COL4A5* variants in 16 males with a median age of 16 years (5 – 55) found that the *COL4A5* variant was severe in 5 (31%) and the additional variant was severe in only 2 (13%)<sup>16, 21, 30-32</sup> (**Table 1**). Digenic disease was associated with proteinuria in 12 (12/13, 92%) and kidney failure in 5 (5/15, 33%) which developed at a median age of 27 (range 23 – 47), as well as hearing loss (6/10, 60%) and ocular abnormalities (3/6, 50%). In one study there were more affected boys with proteinuria<sup>21</sup> but there was no difference in the median age at kidney failure of 24 years compared with 23 years without the additional *COL4A3* or *COL4A4* variant ( $p=0.75$ , comparison with LOVD results) (**Figure 1b**)(**S Table 1**). Digenic Alport syndrome with a hypomorphic *COL4A5* and a further pathogenic *COL4A3* or *COL4A4* variant may be associated with more severe disease with earlier onset proteinuria and a younger age at kidney failure, but there is no evidence for this currently.

**Pathogenic variants in *COL4A5* plus *COL4A3* or *COL4A4* in females.** Twice as many females inherit a pathogenic *COL4A5* variant because they have two X chromosomes<sup>27</sup>. This means that they are therefore twice as likely to have digenic disease with a pathogenic *COL4A5* variant plus a pathogenic *COL4A3* or *COL4A4* variant.

Overall, in such females the pathogenic *COL4A5* variant affects half the heterotrimers and the additional *COL4A3* or *COL4A4* variant means then that 75% of the heterotrimers are defective (**Figure 2a**)<sup>16</sup>. However, the situation is more complicated because inheritance is different for *COL4A5* where there is X chromosome inactivation, and for *COL4A3* or *COL4A4* variants. A severe *COL4A5* variant results in the loss of collagen IV  $\alpha3\alpha4\alpha5$  heterotrimer from on average half the cells, whereas a severe *COL4A3* or *COL4A4* variant results in half the collagen IV  $\alpha3\alpha4\alpha5$  heterotrimers in each cell. For a mild *COL4A5* variant, on average half the cells have a defective heterotrimer, and for a mild *COL4A3* or *COL4A4* variant, half the heterotrimers in each cell are defective.

Data were available from 26 females with a pathogenic *COL4A5* variant and a *COL4A3* or *COL4A4* variant and with a median age of 13 years (range 3 – 55), (**Table 2**)<sup>15, 16, 21, 30, 33-37</sup>. In 7 cases (27%) the *COL4A5* variant was severe. Sixteen (62%) had proteinuria which had developed at a median of 22 years (range 3 – 45) and only two had kidney failure which

developed at 40 and 44 years, respectively. Three (15%) had a hearing loss and one (7%) had unspecified ocular abnormalities. There was GBM lamellation in 5 of 6 examined (83%) and GBM thinning in one of 6 (17%). At present, too few women have been described with digenic variants that include a *COL4A5* variant, to demonstrate an earlier age at kidney failure. However when compared with women with severe *COL4A5* variants<sup>37</sup>, women with pathogenic digenic changes demonstrated a trend to proteinuria at a younger age ( $p=0.09$ ) (**Figure 2b**).

Thus, women with digenic disease that includes a *COL4A5* variant have an increased risk of developing proteinuria, which also increases their risk of kidney failure<sup>7</sup>. This suggests that women with digenic disease that includes a pathogenic *COL4A5* variant have a worse prognosis than those with only a pathogenic variant in *COL4A5*.

**Course.** The clinical course depends on the sex of the affected individual and the severity of both the *COL4A5* and the *COL4A3* or *COL4A4* variant and whether both variants are individually associated with severe disease.

**Management.** Previous guidelines for the management of Alport syndrome have addressed digenic forms of the disease<sup>5, 14, 38, 39</sup>. These are summarised here.

All individuals who undergo testing for Alport syndrome should be examined for variants in all the *COL4A3*, *COL4A4* and *COL4A5* genes since additional pathogenic variants in these genes may worsen clinical features.

Males with digenic variants that include a pathogenic *COL4A5* variant should typically be treated from the time of diagnosis with renin-angiotensin-aldosterone blockade<sup>38</sup>. Females with a digenic variant that includes a pathogenic *COL4A5* variant should be treated from the time of diagnosis because of their increased risk of proteinuria and kidney failure<sup>38</sup>. These recommendations should be applied less stringently in children because of the risk of severe dehydration with vomiting and diarrhoea that are more common in a paediatric age group.

All first degree family members should undergo genetic testing since they may have both pathogenic variants or only one, and half the sons of an affected woman may themselves develop kidney failure with only the *COL4A5* variant<sup>39</sup>.

Individuals with digenic disease should be discouraged from kidney donation because of their own risk of kidney failure<sup>14, 39</sup>.

Inheritance is complicated and easier to understand if the variants are considered separately. Advice about the disease in future generations will be different in males and females with a pathogenic *COL4A5* variant.

#### **Pathogenic heterozygous variants in *COL4A3* plus *COL4A4***

**Population frequency.** Based on population studies, digenic disease with a pathogenic variant in *COL4A3* plus a pathogenic variant in *COL4A4* is more common than a pathogenic variant in *COL4A5* plus one in *COL4A3* or *COL4A4* because pathogenic *COL4A3* and *COL4A4* variants are more common<sup>1</sup>. This form of digenic disease is predicted to affect about one in



200 (for the approximate frequency of a pathogenic *COL4A3* variant) x one in 200 (for the *COL4A4* variant) = one in 40,000 of the population, or one in 200 of those with suspected familial haematuria (where the index case has haematuria and is likely to have a pathogenic heterozygous (*COL4A3* or *COL4A4* variant)). About 0.5% of all *COL4A3* or *COL4A4* variants have a second variant since digenic disease must include a second variant in the other gene. This is about 5 times as often as the combination of a pathogenic variants in *COL4A5* and another in *COL4A3* or *COL4A4*.

**Inheritance.** Because *COL4A3* and *COL4A4* occur back-to-back on chromosome 2 with a short intervening sequence<sup>40</sup>, the two pathogenic variants in *COL4A3* and *COL4A4* may occur on the same (*in cis*) or different (*in trans*) chromosomes. These different patterns affect the mode of inheritance and whether disease occurs in successive generations. Where both variants occur on the same chromosome, they are inherited together in consecutive generations and the pattern mimics autosomal dominant inheritance. This occurs in about half the cases, and only one parent is affected, with a digenic phenotype and typically haematuria.

Thus for an affected male or female with pathogenic variants in both *COL4A3* and *COL4A4*, half their children inherit both pathogenic variants and have digenic disease. Successive generations with the digenic variants will pass these on to half their children in each generation.

In contrast, when the abnormal *COL4A3* and *COL4A4* genes affect different chromosomes, which also occurs in half the cases, both parents are affected typically with haematuria, and the inheritance pattern mimics that of autosomal recessive disease.

Thus for an affected male or female with pathogenic variants in both *COL4A3* and *COL4A4* on different chromosomes, on average half their children have the pathogenic *COL4A3* or *COL4A4* variant, but none have digenic disease.

There may, however, be an ascertainment bias in the reporting of families with these two inheritance patterns, since individuals with variants on different chromosome are likely to have more severe disease and to undergo genetic testing.

**Pathogenesis.** A single pathogenic variant in *COL4A3* or *COL4A4* in both males and females results in 50% of the collagen IV  $\alpha3\alpha4\alpha5$  heterotrimers being defective, but two pathogenic variants in these genes result in 75% of the heterotrimers being defective<sup>16</sup> (**Figure 3a**).

**Clinical features.** The phenotype of a single pathogenic heterozygous variant is typically haematuria, while proteinuria is less common, and kidney failure is uncommon, and hearing loss and ocular abnormalities are rare. Hearing loss occurs from many other causes but any ocular abnormalities in an individual with a single pathogenic variant should undergo a rigorous examination for a further pathogenic variant in the *COL4A3* – *COL4A5* genes.

The cohort of 32 individuals reported with digenic pathogenic variants in *COL4A3* plus *COL4A4*<sup>9, 15, 16, 36, 41, 42</sup> included 10 males and 15 females, with a median age of 34 years (1 to 66), where there was no severe variant in 15 (47%), one in 12 (38%) and two in 5 (16%)

individuals (**Table 3, S Table 3**). Nineteen (66%) had proteinuria which was the same as for AD disease of a hospital-based cohort (65%), and the median age at kidney failure was 54 years (n=8) which was later than for autosomal recessive Alport syndrome<sup>43</sup> (23, range 10 – 38, , p=10<sup>-6</sup>) and younger than for autosomal dominant Alport syndrome<sup>9</sup>(66, range 58 – 73, p=0.01) (**Figure 3b**). In addition, four (27%) had a hearing loss which was more often than for autosomal dominant Alport syndrome but less often than for autosomal recessive disease (23/35, 67%). None had an ocular abnormality. One individual had GBM lamellation, and two had membrane thinning. Thus, the risk of kidney failure for a pathogenic heterozygous *COL4A3* or *COL4A4* variant on its own is very small but the addition of a further pathogenic change may increase this risk.

**Course.** Again the clinical course depends largely on the nature of the underlying pathogenic variants, but it appears that the risk of proteinuria is increased with digenic variants in *COL4A3* and *COL4A4* compared with that of pathogenic heterozygous variants.

**Management.** Again these recommendations appear in various Expert guidelines<sup>5, 14, 38, 39</sup> and they are consistent with the recommendations for digenic disease due to a pathogenic *COL4A5* plus a *COL4A3* or *COL4A4* variant. Individuals with digenic variants should be treated from the time of diagnosis<sup>38</sup>. As for other forms of Alport syndrome it is important to minimise the amount of proteinuria and to control the blood pressure<sup>5, 14</sup>. At risk first degree family members should undergo genetic testing<sup>14</sup>. First degree family members should be strongly discouraged from kidney donation<sup>14</sup>. Inheritance is complicated and easiest to understand if variants are considered separately.

### **Conclusion**

In conclusion, digenic variants are rare but recognised increasingly, their inheritance is complicated and, except for X-linked Alport syndrome in males, where the phenotype is already severe, are probably associated with increased proteinuria and an earlier age at kidney failure. Individuals with digenic variants should be treated early, their affected family members identified and also treated, and all those with digenic variants dissuaded from kidney donation.

Many digenic variants are probably overlooked especially where the second variant is hypomorphic. There are also occasional reports of digenic variants being associated with secondary FSGS and with cystic kidney disease as happens with other *COL4A3* – *COL4A5* variants.

There are still few data on GBM lamellation, hearing loss and ocular abnormalities in digenic disease with pathogenic *COL4A3* and *COL4A4* variants but the data on age at proteinuria suggest that the phenotype is intermediate between AD and AR Alport syndrome.

### **Conflicts of Interest**

The authors have no Conflicts of Interest to declare.

### **Acknowledgements**

The authors have no Conflicts of Interest to declare.

**Funding**

There are no funding sources to acknowledge.

## List of Tables and Figures

**Table 1: Clinical features in males with digenic Alport syndrome where one variant affects COL4A5 compared with features with one pathogenic COL4A5 variant only**

**Table 2: Clinical features in females with digenic Alport syndrome where one variant affects COL4A5 compared with features with one pathogenic COL4A5 variant only**

**Table 3: Clinical features in digenic Alport syndrome where pathogenic variants affect COL4A3 and COL4A4 compared with AR (Storey, 2013) or AD (Furlano, 2020) Alport syndrome**

## List of Figures

**Figure 1a. Effect of digenic COL4A5 plus COL4A3/COL4A4 variants on heterotrimer formation in males<sup>16</sup>**

**Figure 1b: Kidney survival in males with a COL4A5 variant (from LOVD) compared with a COL4A5 plus a COL4A3 or COL4A4 variant**

The data and references for the digenic variants are summarised in Table 1 and full data provided in STable 1. COL4A5 variant (solid line); COL4A5 plus a COL4A3 or COL4A4 variant (dashed line)

**Figure 2a. Effect of digenic COL4A5 plus COL4A3/COL4A4 variants on heterotrimer formation in females<sup>16</sup>**

**Figure 2b: Proteinuria in females with a COL4A5 variant (Mastrangelo, 2020) compared with a COL4A5 plus a COL4A3 or COL4A4 variant (S Table 2)**

The data and references for the digenic variants are summarised in Table 2 and full data is provided in STable 2. COL4A5 variant (solid line); COL4A5 plus a COL4A3 or COL4A4 variant (dashed line)

**Figure 3a. Effect of digenic COL4A3 plus COL4A4 variants on heterotrimer formation<sup>16</sup>**

**Figure 3b: Kidney survival in digenic Alport syndrome where pathogenic variants affect COL4A3 and COL4A4 compared with autosomal recessive (Storey, 2013) or autosomal dominant (Furlano, 2020) Alport syndrome**

The data and references for the digenic variants are summarised in Table 3 and full data is provided in STable 3. Heterozygous variants (solid line), digenic variants (dotted line) and autosomal recessive variants (dashed line)

**Table 1: Clinical features in males with digenic Alport syndrome where one variant affects COL4A5 compared with features with one pathogenic COL4A5 variant only**

	X-linked Alport syndrome in males (n=315, Jais 2000)	X-linked Alport syndrome in males after ACE treatment (n=282, Yamamura 2020)	Digenic Alport syndrome in males including COL4A5 variant (n=16)
Age (median, range, years)	Not provided	13 (0 – 73)	16 (5 – 55)
COL4A5 – severe variant	75/195 families (38%)	125 (47%)	5 (31%)
p.G624D in COL4A5	Not specified	0	4
COL4A3	Not applicable	Not applicable	11
COL4A4	Not applicable	Not applicable	5
Additional variant is severe	Not applicable	Not applicable	2/16
GBM lamellation, splitting or basket-weave pattern	88/98 (90%) at a mean age of 12.5 years	Not specified	5/5
GBM thinning	12/98 (12%) at mean age of 11 years	Not specified	Not specified
Abnormal collagen IV $\alpha3\alpha4\alpha5$ immuno-histochemistry	14/16 (88%)	64/146 (44%)	Not specified
Haematuria	191/193 (99%)	262/264 (99%)	14/14 (100%)
Proteinuria	207/218 (95%)	238 (91%)	12/13 (92%)
Number with kidney failure	282/360 (78%)	61/282 (22%)	5/15 (33%)
Age at kidney failure (median, years)	25 (9 - >41)	35 (32 – 40)	25 (23 to 47)
Hearing loss	239/303 (79%)	77 (32%)	6/10 (60%)
Ocular abnormalities	57/162 (35%)	13 (6%)	3/6 (50%)

‘Severe’ COL4A5 variants include major rearrangements, truncating and splice site variants; GBM glomerular basement membrane. Precise numbers were not always provided but have been deduced from % or figures in manuscript.

**Table 2: Clinical features in females with digenic Alport syndrome where one variant affects COL4A5 compared with features with one pathogenic COL4A5 variant only**

	X-linked Alport syndrome in females (n=349, Jais 2003)	X-linked Alport syndrome in females (n=275, Yamamura, 2017)	X-linked Alport syndrome in females (n=24, Mastrangelo, 2020)	Digenic Alport syndrome in females including COL4A5 variant (n=26)
Age (median, range, years)	Not provided	24 (0-92)	8 (1 – 41)	13 (3-55)
COL4A5 – severe variant	191/315 (61%)	138 (50%)	14/24 (58%)	7 (27%)
COL4A3	Not applicable	Not applicable	Not applicable	15
COL4A4	Not applicable	Not applicable	Not applicable	11
Additional variant is severe	Not applicable	Not applicable	Not applicable	7/26 (27%)
GBM lamellation, splitting or basket-weave pattern	20/28 (71%)	Not specified	16/16 (basket-weave in 8/16)	5/6 (83%)
GBM thinning	6/28 (21%)	Not specified	16/16	1/6 (17%)
Abnormal collagen IV $\alpha3\alpha4\alpha5$ immunohistochemistry	7/9 (78%)	Not specified	Not specified	Not specified
Haematuria	309 (96%)	232 (98%)		23/23 (100%)
Proteinuria	176/234 (75%)	175 (73%)	10/24 (42%)	16/26 (62%)
Age at proteinuria onset (median, years)	Not specified	7	13 (5 – 30)	12 (3 – 45)
Number with kidney failure (n,%)	51/288 (18%)	33 (12%)	1/24 (4%)	2/24 (8%)
Age at kidney failure (median, years)	38 (18 – 70)	65	40	40, 44
Hearing loss (n,%)	239/303 (79%)	15 (6%)	4/24 (17%)	3/20 (15%)
Ocular abnormalities	57/162 (35%)	4 (2%)	0/24 (0%)	1/14 (7%)

**Table 3: Clinical features in digenic Alport syndrome where pathogenic variants affect COL4A3 and COL4A4 compared with AR or AD Alport syndrome**

	Digenic Alport syndrome (n=32)	Autosomal dominant Alport syndrome (n=252, Furlano, 2021)	Autosomal recessive Alport syndrome (n=40, Storey, 2013)
Age (median, range, years)	34 (1 -66)	48 (5 – 87)	31 (6 -54)
<i>COL4A3</i>	32	107 (35 families)	20/40 (50%)
<i>COL4A4</i>	32	133 (43 families)	20/40 (50%)
No severe variant	15 (47%)	136 (57%)	8 (20%)
One severe variant	12 (38%)	104 (43%)	12 (30%)
Two severe variants	5 (16%)	NA	20 (50%)
GBM lamellation or splitting	1/3 (33%)	Not specified	34/36 (94%)
GBM thinning	2/3 (67%)	Not specified	2/36 (6%) but biopsy performed as a child
<b>Abnormal collagen IV <math>\alpha3\alpha4\alpha5</math> immuno-histochemistry</b>	Not specified	Not specified	Not specified
<b>Haematuria</b>	Not specified	<b>232/252 (92%)</b>	Not specified
<b>Proteinuria</b>	<b>19/29 (66%)</b>	<b>157/241 (65%)</b>	Not specified
<b>Age at proteinuria onset (median, years)</b>	<b>43 (5 – 59)* taken from age at proteinuria recorded</b>	<b>Not specified</b>	Not specified
<b>Number with kidney failure</b>	<b>8 (25%)</b>	<b>61 (24%)</b>	<b>20/34 (59%)</b>
<b>Age at kidney failure (median, years)</b>	<b>54 (n=8)</b>	<b>67 (58-73)</b>	<b>22.5 (10-38)</b>
<b>Hearing loss</b>	<b>4/15 (27%)</b>	<b>11/131 (8%)</b>	<b>23/35 (67%)</b>
<b>Ocular abnormalities</b>	0/7	2/75 (2%)	10/18 (56%)

## References

1. Gibson J, Fieldhouse R, Chan MMY, Sadeghi-Alavijeh O, Burnett L, Izzi V, et al.: Prevalence Estimates of Predicted Pathogenic COL4A3-COL4A5 Variants in a Population Sequencing Database and Their Implications for Alport Syndrome. *J Am Soc Nephrol*, 32: 2273-2290, 2021 10.1681/ASN.2020071065
2. Lanktree MB, Haghighi A, Guiard E, Iliuta IA, Song X, Harris PC, et al.: Prevalence Estimates of Polycystic Kidney and Liver Disease by Population Sequencing. *J Am Soc Nephrol*, 29: 2593-2600, 2018 10.1681/ASN.2018050493
3. Kashtan CE, Ding J, Garosi G, Heidet L, Massella L, Nakanishi K, et al.: Alport syndrome: a unified classification of genetic disorders of collagen IV alpha345: a position paper of the Alport Syndrome Classification Working Group. *Kidney Int*, 93: 1045-1051, 2018 10.1016/j.kint.2017.12.018
4. Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG: Alport's syndrome, Goodpasture's syndrome, and type IV collagen. *N Engl J Med*, 348: 2543-2556, 2003 10.1056/NEJMra022296
5. Savige J, Gregory M, Gross O, Kashtan C, Ding J, Flinter F: Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy. *J Am Soc Nephrol*, 24: 364-375, 2013 10.1681/ASN.2012020148
6. Gast C, Pengelly RJ, Lyon M, Bunyan DJ, Seaby EG, Graham N, et al.: Collagen (COL4A) mutations are the most frequent mutations underlying adult focal segmental glomerulosclerosis. *Nephrol Dial Transplant*, 31: 961-970, 2016 10.1093/ndt/gfv325
7. Jais JP, Knebelmann B, Giatras I, Marchi M, Rizzoni G, Renieri A, et al.: X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males. *J Am Soc Nephrol*, 11: 649-657, 2000 10.1681/ASN.V114649
8. Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A, et al.: X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a "European Community Alport Syndrome Concerted Action" study. *J Am Soc Nephrol*, 14: 2603-2610, 2003 10.1097/01.asn.0000090034.71205.74
9. Furlano M, Martinez V, Pybus M, Arce Y, Crespi J, Venegas MDP, et al.: Clinical and Genetic Features of Autosomal Dominant Alport Syndrome: A Cohort Study. *Am J Kidney Dis*, 78: 560-570 e561, 2021 10.1053/j.ajkd.2021.02.326
10. Matthaïou A, Poulli T, Deltas C: Prevalence of clinical, pathological and molecular features of glomerular basement membrane nephropathy caused by COL4A3 or COL4A4 mutations: a systematic review. *Clin Kidney J*, 13: 1025-1036, 2020 10.1093/ckj/sfz176
11. Deltas C: Digenic inheritance and genetic modifiers. *Clin Genet*, 93: 429-438, 2018 10.1111/cge.13150
12. Voskarides K, Papagregoriou G, Hadjipanagi D, Petrou I, Savva I, Elia A, et al.: COL4A5 and LAMA5 variants co-inherited in familial hematuria: digenic inheritance or genetic modifier effect? *BMC Nephrol*, 19: 114, 2018 10.1186/s12882-018-0906-5
13. Daga S, Fallerini C, Furini S, Pecoraro C, Scolari F, Ariani F, et al.: Non-collagen genes role in digenic Alport syndrome. *BMC Nephrol*, 20: 70, 2019 10.1186/s12882-019-1258-5
14. Savige J, Lipska-Zietkiewicz BS, Watson E, Hertz JM, Deltas C, Mari F, et al.: Guidelines for Genetic Testing and Management of Alport Syndrome. *Clin J Am Soc Nephrol*, 17: 143-154, 2022 10.2215/CJN.04230321
15. Fallerini C, Baldassarri M, Trevisson E, Morbidoni V, La Manna A, Lazzarin R, et al.: Alport syndrome: impact of digenic inheritance in patients management. *Clin Genet*, 92: 34-44, 2017 10.1111/cge.12919
16. Mencarelli MA, Heidet L, Storey H, van Geel M, Knebelmann B, Fallerini C, et al.: Evidence of digenic inheritance in Alport syndrome. *J Med Genet*, 52: 163-174, 2015 10.1136/jmedgenet-2014-102822
17. Schaffer AA: Digenic inheritance in medical genetics. *J Med Genet*, 50: 641-652, 2013 10.1136/jmedgenet-2013-101713



18. Gazzo A, Raimondi D, Daneels D, Moreau Y, Smits G, Van Dooren S, et al.: Understanding mutational effects in digenic diseases. *Nucleic Acids Res*, 45: e140, 2017 10.1093/nar/gkx557
19. Savige J, Storey H, Il Cheong H, Gyung Kang H, Park E, Hilbert P, et al.: X-Linked and Autosomal Recessive Alport Syndrome: Pathogenic Variant Features and Further Genotype-Phenotype Correlations. *PLoS One*, 11: e0161802, 2016 10.1371/journal.pone.0161802
20. Daga S, Ding J, Deltas C, Savige J, Lipska-Zietkiewicz BS, Hoefele J, et al.: The 2019 and 2021 International Workshops on Alport Syndrome. *Eur J Hum Genet*, 2022 10.1038/s41431-022-01075-0
21. Zhang Y, Ding J, Zhang H, Yao Y, Xiao H, Wang S, et al.: Effect of heterozygous pathogenic COL4A3 or COL4A4 variants on patients with X-linked Alport syndrome. *Mol Genet Genomic Med*, 7: e647, 2019 10.1002/mgg3.647
22. Bateman JF, Boot-Handford RP, Lamande SR: Genetic diseases of connective tissues: cellular and extracellular effects of ECM mutations. *Nat Rev Genet*, 10: 173-183, 2009 10.1038/nrg2520
23. Pieri M, Stefanou C, Zaravinos A, Erguler K, Stylianou K, Lapathitis G, et al.: Evidence for activation of the unfolded protein response in collagen IV nephropathies. *J Am Soc Nephrol*, 25: 260-275, 2014 10.1681/ASN.2012121217
24. Wang D, Mohammad M, Wang Y, Tan R, Murray LS, Ricardo S, et al.: The Chemical Chaperone, PBA, Reduces ER Stress and Autophagy and Increases Collagen IV alpha5 Expression in Cultured Fibroblasts From Men With X-Linked Alport Syndrome and Missense Mutations. *Kidney Int Rep*, 2: 739-748, 2017 10.1016/j.ekir.2017.03.004
25. Pierides A, Voskarides K, Kkolou M, Hadjigavriel M, Deltas C: X-linked, COL4A5 hypomorphic Alport mutations such as G624D and P628L may only exhibit thin basement membrane nephropathy with microhematuria and late onset kidney failure. *Hippokratia*, 17: 207-213, 2013
26. Zurowska AM, Bielska O, Daca-Roszak P, Jankowski M, Szczepanska M, Roszkowska-Bjanid D, et al.: Mild X-linked Alport syndrome due to the COL4A5 G624D variant originating in the Middle Ages is predominant in Central/East Europe and causes kidney failure in midlife. *Kidney Int*, 99: 1451-1458, 2021 10.1016/j.kint.2020.10.040
27. Savige J, Colville D, Rheault M, Gear S, Lennon R, Lagas S, et al.: Alport Syndrome in Women and Girls. *Clin J Am Soc Nephrol*, 11: 1713-1720, 2016 10.2215/CJN.00580116
28. Kashtan CE, Gross O: Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020. *Pediatr Nephrol*, 36: 711-719, 2021 10.1007/s00467-020-04819-6
29. Yamamura T, Horinouchi T, Nagano C, Omori T, Sakakibara N, Aoto Y, et al.: Genotype-phenotype correlations influence the response to angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndrome. *Kidney Int*, 98: 1605-1614, 2020 10.1016/j.kint.2020.06.038
30. Choi M, Anistan YM, Eckardt KU, Gollasch M, Nickel P: Possible Digenic Disease in a Caucasian Family with COL4A3 and COL4A5 Mutations. *Nephron*, 141: 213-218, 2019 10.1159/000495764
31. Domingo-Gallego A, Pybus M, Bullich G, Furlano M, Ejarque-Vila L, Lorente-Grandoso L, et al.: Clinical utility of genetic testing in early-onset kidney disease: seven genes are the main players. *Nephrol Dial Transplant*, 2021 10.1093/ndt/gfab019
32. Zhang L, Sun BC, Zhao BG, Ma QS: An overview of the multi-pronged approach in the diagnosis of Alport syndrome for 22 children in Northeast China. *BMC Nephrol*, 21: 294, 2020 10.1186/s12882-020-01962-y
33. Daga S, Baldassarri M, Lo Rizzo C, Fallerini C, Imperatore V, Longo I, et al.: Urine-derived podocytes-lineage cells: A promising tool for precision medicine in Alport Syndrome. *Hum Mutat*, 39: 302-314, 2018 10.1002/humu.23364
34. Han KH, Park JE, Ki CS: De novo mutations in COL4A5 identified by whole exome sequencing in 2 girls with Alport syndrome in Korea. *Korean J Pediatr*, 62: 193-197, 2019 10.3345/kjp.2018.06772
35. Yokota K, Nozu K, Minamikawa S, Yamamura T, Nakanishi K, Kaneda H, et al.: Female X-linked Alport syndrome with somatic mosaicism. *Clin Exp Nephrol*, 21: 877-883, 2017 10.1007/s10157-016-1352-y

36. Zhao X, Chen C, Wei Y, Zhao G, Liu L, Wang C, et al.: Novel mutations of COL4A3, COL4A4, and COL4A5 genes in Chinese patients with Alport Syndrome using next generation sequence technique. *Mol Genet Genomic Med*, 7: e653, 2019 10.1002/mgg3.653
37. Mastrangelo A, Giani M, Groppali E, Castorina P, Solda G, Robusto M, et al.: X-Linked Alport Syndrome in Women: Genotype and Clinical Course in 24 Cases. *Front Med (Lausanne)*, 7: 580376, 2020 10.3389/fmed.2020.580376
38. Savige J, Ariani F, Mari F, Bruttini M, Renieri A, Gross O, et al.: Expert consensus guidelines for the genetic diagnosis of Alport syndrome. *Pediatr Nephrol*, 34: 1175-1189, 2019 10.1007/s00467-018-3985-4
39. Savige J, Storey H, Watson E, Hertz JM, Deltas C, Renieri A, et al.: Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome: refining the ACMG criteria. *Eur J Hum Genet*, 29: 1186-1197, 2021 10.1038/s41431-021-00858-1
40. Hudson BG, Reeders ST, Tryggvason K: Type IV collagen: structure, gene organization, and role in human diseases. Molecular basis of Goodpasture and Alport syndromes and diffuse leiomyomatosis. *J Biol Chem*, 268: 26033-26036, 1993
41. Rungtung I, Sahay M, Dalal A: Digenic variations of human COL4A3 and COL4A4 genes result in early onset renal failure *Gene Reports*, 19, 2020
42. Kamiyoshi N, Nozu K, Fu XJ, Morisada N, Nozu Y, Ye MJ, et al.: Genetic, Clinical, and Pathologic Backgrounds of Patients with Autosomal Dominant Alport Syndrome. *Clin J Am Soc Nephrol*, 11: 1441-1449, 2016 10.2215/CJN.01000116
43. Storey H, Savige J, Sivakumar V, Abbs S, Flinter FA: COL4A3/COL4A4 mutations and features in individuals with autosomal recessive Alport syndrome. *J Am Soc Nephrol*, 24: 1945-1954, 2013 10.1681/ASN.2012100985

## Supplementary Materials

### Supplementary Methods

Individuals provided informed consent to the use of their deidentified clinical data at the time of testing or their data in publications or databases were considered to be in the public domain.

Kaplan-Meier plots of kidney survival were constructed as follows.

Males with X-linked Alport syndrome and a pathogenic *COL4A5* variant were identified from LOVD (<https://databases.lovd.nl/shared/genes/COL4A5>) and age at kidney failure extracted. Age at kidney failure was the age at the diagnosis of kidney failure, or where this was not available, the commencement of dialysis, or at first kidney transplant. Affected male family members were included separately. Where only median or mean age at kidney failure was reported for a family, this was used instead. Where a male had not yet progressed to kidney failure, his age at most recent examination was included as a censored data point. Kidney survival curves were compared using the log-rank test.

Survival analysis was performed in R (version 3.6.2) using the *survival* and *survminer* packages <sup>1,2,3</sup>.

### Supplementary Tables

**Supplementary Table 1: Genotype-phenotype correlation in males with digenic Alport syndrome including a *COL4A5* variant**

**Supplementary Table 2: Genotype-phenotype correlation in females with digenic Alport syndrome including a *COL4A5* variant**

**Supplementary Table 3: Genotype-phenotype correlation in males and females with digenic Alport syndrome with a *COL4A3* and *COL4A4* variant**

### References

1. Therneau T: A Package for survival analysis in R. R package version 3.2-11. <https://CRAN.R-project.org/package=survival>. 2021
2. Therneau TM, Grambsch PM: *Modeling survival data: Extending the Cox model*, New York, Springer, 2000
3. Kassambara A, Kosinski M, Biecek P: *survminer: Drawing survival curves using 'ggplot2'*. R package version 0.4.9. <https://CRAN.R-project.org/package=survminer>. 2021